



SMI CHEMO INFUSION COLD COMPRESSION WRAPS

Improving Patient Quality of Life by Alleviating CIPN

What is CIPN?

Chemotherapy-Induced Peripheral Neuropathy occurs when the cancer-fighting drugs damage nerves in the hands and feet.



Patients may experience:

- Burning or shooting pain
 - Tingling or numbness
 - Long-term impairment and increased morbidity
- Reduced quality of life



“Cryo-compression therapy can significantly decrease chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer.”
 — Mary Katherine Montes de Oca, MD, Duke University*

“What I was not at all prepared for, however, was CIPN. Though I had been placed on two of the top culprits for this affliction, Paclitaxel (Taxol) and Carboplatin, I received no pre-treatment or CIPN prevention education on cryotherapy despite its efficacy having been proven for over a decade in patients receiving taxane and platinum-based therapies or other neuro-toxic agents.”
 — Laura L., RN MSN, ovarian and endometrial cancer survivor

- The SMI Cold Therapy Chemo Infusion Wrap uses the same concept, clinically proven and **TRUSTED BY OVER 600 MEDICAL FACILITIES** nationwide, to reduce pain and swelling for post-operative orthopedic patients.
- SMI gel bags will deliver **3+ HOURS OF CONTINUOUS COLD THERAPY**
- Multiple compression straps securely hold the wrap in place comfortably and ensure effective cold therapy delivery and temperature control.
- Universal fit for the hands and feet; the same wrap fits both.
- Effective, well-tolerated cryotherapy with simple, hassle-free application.
- Freezers provided at **NO CHARGE**

Sources:

- *Quote: <https://www.oncnursingnews.com/view/mary-katherine-montes-de-oca-on-cryo-compression-therapy-for-peripheral-neuropathy-in-gynecologic-cancers>
- Global CIPN Estimates: <https://doi.org/10.1136/rapm-2024-106229>
- Cryotherapy for CIPN Prevention: [https://www.thebreastonline.com/article/S0960-9776\(24\)00094-8/fulltext](https://www.thebreastonline.com/article/S0960-9776(24)00094-8/fulltext)

MADE IN THE USA

>85%

of adult cancer patients experience CIPN worldwide



>70%

of patients who are administered Taxane and platinum agents experience CIPN within the first month of treatment




A 2026 Tennessee Oncology Evidence-Based Practice Quality Improvement Project Showed:

96%
of patients experienced no CIPN

4%
of patients developed Grade 1 CIPN (baseline) and were asymptomatic

100%
of patients maintained quality of life with minimal workflow disruptions and no treatment delays



Contact us
877.ICE.WRAP
smicoldtherapy.net/